IBA AND ELEKTA INITIATE GLOBAL PARTICLE THERAPY PROGRAM AT ASTRO

IBA AND ELEKTA INITIATE GLOBAL PARTICLE THERAPY PROGRAM AT ASTRO

PRESS RELEASE	
Los Angeles, CA, October 27, 2007

IBA (Ion Beam Applications S.A.: Reuters IBAB.BR and Bloomberg IBAB.BB) and
Elekta AB (publ) (Stockholm, Sweden: EKTA.ST), edtoday announced a global
particle therapy collaboration program to optimize the seamless integration of
proton therapy delivery and information management systems within the radiation
oncology environment. Both companies currently showcase their products at the
49th Annual Meeting of ASTRO (American Society for Therapeutic Radiology and
Oncology) held in Los Angeles, CA, USA, from October 28 to November 1, 2007.

The aim of this collaboration program is to offer fully integrated, open and
comprehensive cancer treatment solutions to the particle therapy market. Both
companies have unique competence in their respective fields of radiation therapy
and have decided to join forces to simplify the integration of the many
components that is necessary in an advanced proton therapy center. Dynamic
coordinated integration of both linear accelerator and particle therapy
environments will have significant added value for front-line medical
institutions fighting cancer. IBA and Elekta both supply world-leading
technology and share the philosophy of open architecture and industry standards.


Under this collaboration agreement IBA and Elekta will provide particle therapy
solutions packages to meet specific clinical requirements. On the Elekta
side,this can include an array of Elekta products and solutions such as the
MOSAIQ™ workflow management and information system (OIS), MOSAIQ Proton Therapy
module, patient immobilization devices, localization systems, and even the
Elekta Synergy® advanced IMRT and IGRT delivery system. On the IBA side, the
agreement includes the comprehensive Proteus system. More components and
solutions may be added in the future based on customer requirements.

The collaboration will also include joint development of future integrated
solutions that will offer the most added-value to the world wide proton therapy
customers in their daily activities. Complementing this development agreement,
the two companies will also join forces in the field of Sales and Marketing,
offering optimized commercial solutions to an extended market.

“The IBA proton therapy solution is intrinsically open to interface with any
radiation therapy system. However, as cancer centers expect the Oncology
Information System (OIS) software and other radiation therapy equipment to
operate seamlessly and intelligently with the proton therapy system, the IBA and
Elekta joint development will make proton therapy system a benchmark of
integration”, said Pierre Mottet, Chief Executive Officer of IBA.

“Radiation therapy is currently undergoing rapid transformation in many areas.
Intensity modulation, image guidance and workflow enhancing information
management systems are today changing the face of cancer care all over the
world. Just as Elekta is the driving force behind most of these improvements on
the linear accelerator, IBA has demonstrated their dominant leadership in
particle therapy technology and our common customers use our products with the
IBA system with great satisfaction.” said Tomas Puusepp, President and CEO of
Elekta. “Thanks to the fact that we share the vision of open systems design
approach together with joint informal cooperation in the past, we have been able
to quickly find common ground, both technically and commercially. Together, IBA
and Elekta will be able to offer an optimal solution for every need at a
comprehensive cancer center,” Puusepp concluded. 

******



For further information, please contact:


IBA:
Paul-Emmanuel Goethals, Director, Corporate Business Development & Investor
Relations 	
Tel: +32 10 47 58 16, e-mail: paul-emmanuel.goethals@iba-group.com

Elekta Investor inquires:
Peter Ejemyr, Group VP Corporate Communications
Tel: +46 733 611 000 (mobile), e-mail: peter.ejemyr@elekta.com

Elekta Product inquiries: 
Peter J. Gaccione, Vice President, Global Marketing,
Tel: +1 770-670-2380, e-mail: peter.gaccione@elekta.com
About IBA
IBA delivers solutions of exceptional precision in the fields of cancer
diagnosis and therapy. The company also provides sterilization and ionization
solutions to improve the hygiene and safety of everyday life. IBA is the
undisputed world market leader in Proton Therapy, with more than 50% market
share. The company is present in over 40 sites in North America, Europe and Asia
with 1,300 employees and its products range are present in over 5,000 hospitals,
medical imaging centers and cancer therapy centers around the world. IBA is
listed on the pan-European stock exchange EURONEXT, is integrated into the Next
Economy market segment, and belongs to the BelMid index. Website:
http://www.iba-worldwide.com.


About Elekta

Elekta is an international medical technology group, providing oncologists,
radiation therapists, neurosurgeons and many other medical specialists with
state of the art tools to fight serious disease.

Elekta provides advanced clinical solutions, comprehensive management and
information systems as well as services for improved cancer care and management
of brain disorders. 

Elekta's systems and solutions are used in over 4,500 hospitals around the
world. Clinical and information management solutions include, among others,
Leksell Gamma Knife® for non-invasive treatment of brain disorders, Elekta
Axesse™ and Elekta Synergy® for stereotactic and image guided radiation therapy
and radiosurgery as well as the MOSAIQ™ suite of software for image-enabled EMR
and efficient management of clinical and patient data.

With over 2,000 employees globally, the corporate headquarter is located in
Stockholm, Sweden and the company is listed on the Nordic Exchange under the
ticker EKTAb. More information about Elekta can be found at www.elekta.com.